Trademarkia Logo

Canada

C$
T & DESIGN
REGISTERED

on 18 Nov 2020

Last Applicant/ Owned by

TITAN PHARMACEUTICALS INC.

400 Oyster Point Boulevard, Suite 505 South San Francisco, CA 94080

US

Serial Number

1843050 filed on 16th Jun 2017

Registration Number

TMA1087959 registered on 18th Nov 2020

Registration expiry Date

18th Nov 2030

Correspondent Address

OSLER, HOSKIN & HARCOURT LLP

Suite 320, World Exchange Plaza100 Queen StreetOttawa,

ONTARIO

CA

K1P1J9

T & DESIGN

Trademark usage description

pharmaceuticals, namely, treatment for central nervous disorders, namely, central nervous system infections, brain diseases, central nervous system mo Read More

Vienna Information


26 . 7 . 3

Circles or ellipses with one or more triangles and/or lines forming an angleCercles ou ellipses avec un ou plusieurs triangles et/ou lignes formant un angle

26 . 1 . 1

CirclesCercles

26 . 1 . 3

One circle or ellipseUn cercle ou une ellipse

26 . 3 . 1

One triangleUn triangle

26 . 3 . 5

Triangles pointing downwardsTriangles avec la pointe en bas

26 . 3 . 10

Triangles containing one or more circles, ellipses or polygons (except 26.3.11)Triangles contenant un ou plusieurs cercles, ellipses ou polygones (excepté 26.3.11)

26 . 3 . 19

Triangles with inscriptions projecting beyond one or more of the sides thereofTriangles avec inscriptions débordant un ou plusieurs côtés

26 . 3 . 24

Triangles with dark surfaces or parts of surfacesTriangles avec surface ou partie de la surface foncée

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 21

One letterUne lettre

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 6

White, grey, silverBlanc, gris, argent

Classification Information


Class [005]
Pharmaceuticals, namely, treatment for central nervous disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, Parkinson's disease, restless leg syndrome, opioid use disorder, chronic pain and cancer, hematological disorders, endocrine disorders, namely, growth and thyroid disorders, and cancer, metabolic disorders, namely, obesity, hyperlipidemia, diabetes, and hypertension, inflammatory disorders, namely, inflammatory joint diseases, inflammatory skin diseases, inflammatory diseases affecting articulating cartilage, connective tissues, tendons and ligaments, inflammatory of muscle tissues, inflammatory diseases of the eyes, inflammatory diseases of the middle and inner ear, inflammatory diseases of the nasal and paranasal passages and sinuses, arthritis and rheumatoid arthritis, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, namely, cancer, atherosclerosis, stroke, anemia, heart attack, congestive heart failure, hypertension, intestinal disorders, namely, gastro-intestinal diseases, and cancer, bone disease, autoimmune disorders and disorders of the immune systems, infectious diseases, namely, respiratory infections, eye infections, topical infections, malaria, parasitic infections, bacterial infections, viral infections and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, Parkinson's disease, restless leg syndrome, opioid use disorder, chronic pain and cancer and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, namely, growth and thyroid disorders, and cancer, metabolic disorders, namely, obesity, hyperlipidemia, diabetes, and hypertension, inflammatory disorders, namely, inflammatory joint diseases, inflammatory skin diseases, inflammatory diseases affecting articulating cartilage, connective tissues, tendons and ligaments, inflammatory of muscle tissues, inflammatory diseases of the eyes, inflammatory diseases of the middle and inner ear, inflammatory diseases of the nasal and paranasal passages and sinuses, arthritis and rheumatoid arthritis, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, namely, cancer, atherosclerosis, stroke, anemia, heart attack, congestive heart failure, hypertension, intestinal disorders, namely, gastro-intestinal diseases, and cancer, bone disease, autoimmune disorders and disorders of the immune systems, infectious diseases, namely, respiratory infections, eye infections, topical infections, malaria, parasitic infections, bacterial infections, viral infections and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymerbased matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases.


Classification kind code

11

Mark Details


Serial Number

1843050

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 42
on 26th Feb 2020
Advertised
Submitted for opposition 27
on 7th Feb 2020
Approval Notice Sent
Submitted for opposition 26
on 7th Feb 2020
Approved
Submitted for opposition 12
on 15th May 2019
Extension of Time
Submitted for opposition 15
on 14th Dec 2018
Correspondence Created
Submitted for opposition 22
on 11th Jun 2018
Search Recorded
Submitted for opposition 20
on 11th Jun 2018
Examiner's First Report
Submitted for opposition 31
on 20th Jun 2017
Formalized
Submitted for opposition 30
on 16th Jun 2017
Filed
Submitted for opposition 1
on 16th Jun 2017
Created